Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial NCT05945823 active not recruiting, primary completion Mar 2026. No public readout of phase 2 ORR results found in searches. Prior phase 1b data (1532P) showed ORR 39% in ICI-naive esophageal pts but not phase 2 specific. Insufficient evidence for positive/negative framing.
Found Apr 6, 2026, 2:58 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed85% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial is active, not recruiting with primary completion in Mar 2026. No public results or readouts found for NCT05945823. Related but distinct futibatinib+pembro trials exist; this specific Phase 2 combo with SoC in solid tumors has no efficacy data yet.
Found Apr 6, 2026, 2:10 PMReviewed Apr 6, 2026, 2:25 PM
NO_DECISIONDismissed90% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.
Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No public efficacy readout was found for this exact Phase 2 trial. The best current evidence shows it is still ongoing/active and had not reported results as of late March 2026, so there is no trial-specific basis to call the readout positive or negative.
Found Apr 3, 2026, 4:30 PMReviewed Apr 3, 2026, 4:47 PM
Web Searchfdaaa.trialstracker.netAug 1, 2025, 12:00 AM
NCT05945823: An ongoing trial by Taiho Oncology, Inc.
Trial tracker labels NCT05945823 as ongoing; results status ongoing, completion date March 31, 2026, and actual reporting date none. Last checked at ClinicalTrials.gov on March 26, 2026.
Web Searchcenterwatch.comDec 1, 2025, 12:00 AM
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
CenterWatch lists NCT05945823 as a Phase 2 study recruiting/active in esophageal and pancreatic settings and describes treatment arms, but provides no public efficacy outcome or readout.
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific public efficacy readout was found. The cited registries still describe NCT05945823 as ongoing/active, with results status ongoing and no actual results reporting date. Without a clear public readout framed as positive or negative for this exact Phase 2 trial, classification is no_decision.
Found Apr 1, 2026, 7:50 PMReviewed Apr 1, 2026, 8:21 PM
Web Searchfdaaa.trialstracker.netMar 18, 2026, 12:00 AM
NCT05945823: An ongoing trial by Taiho Oncology, Inc.
TrialTracker lists NCT05945823 as ongoing, with Results Status: Ongoing and Actual reporting date: None; required reporting date is March 31, 2027.
Web Searchctis.eu
Phase 2 Futibatinib in Combination with PD-1 Antibody-based Standard of Care in Solid Tumors | CTIS.eu
EU CTIS entry for the same study (protocol TAS-120-206) shows status: Ongoing, recruitment ended, not a completed trial with posted efficacy results.
ClinicalTrialsvanderbilt.trialstoday.orgDec 24, 2025, 12:00 AM
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
ClinicalTrials-derived listing for NCT05945823 shows Status: Active, not recruiting and describes the study objectives, but provides no public outcome/readout.